Schizoaffective Disorders Completed Phase 2 Trials for Bifeprunox (DB04888)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00141479To Evaluate the Impact of Treatment Interruption on Re-initiation of BifeprunoxTreatment
NCT00139919Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar DisorderTreatment
NCT00139906Twice Daily Titration Study of Bifeprunox in Subjects With SchizophreniaTreatment